RxDoctor Payments Data

Yudh Gupta

Nephrology · Washington, DCNPI 1215008982

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $582 of the $677 with a category attached, or 86.0%. 5 manufacturers reported payments, led by Ardelyx, Inc. at 40.2% of the total.

$677in general payments, 2019–2025

Across 7 payments — averaging $96.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ardelyx, Inc.$272
  • Fresenius USA Marketing, Inc.$139
  • AstraZeneca$104
  • Mallinckrodt Hospital Products Inc.$95
  • Baxter Healthcare$66

What the payments were for

  • Food & beverage$58286%
  • Education$9514%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$677 in reported general payments places this provider in the 55th percentile of 62 nephrology providers in District of Columbia.

See all nephrology providers in District of Columbia

Medicare billing

Part B allowed, 2024
$592,278
Medicare patients
596
Services billed
3,523

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide39$150,570
Sevelamer Carbonate229$58,386
AuryxiaFerric Citrate17$40,616
ProsolParenteral Amino Acid 20% No.1112$16,754
EliquisApixaban16$14,438
Calcium Acetate45$5,203
Clonidine23$3,558
Midodrine Hcl56$3,217
Nifedipine ErNifedipine56$1,559
Labetalol Hcl26$1,286
Hydroxyzine Hcl24$1,168
Clonidine Hcl62$938
Hydralazine Hcl77$896
Albuterol Sulfate HfaAlbuterol Sulfate33$844
Amlodipine Besylate108$573

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$139$150,57039 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 62 nephrology providers in District of Columbia.

Other nephrology in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →